Drug Trial Radar · NCT00050375
Clinical Trial for Ovarian Cancer (OvaRex®)
Last checked: Nov 19, 2026Latest source record: Dec 18, 2007 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
354
Actual
Start
Dec 2002
Primary completion
Not stated
Study completion Dec 2007
Sponsor
- Lead sponsor
- Unither PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Dec 6, 2002
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will compare the time to disease relapse between OvaRex® MAb-B43.13-treated patients and placebo-treated patients. This study will also compare assessments of survival, quality of life, immune response and safety between active and placebo groups.
Conditions
- Ovarian Cancer
Interventions
oregovomabDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
No primary outcomes listed.
Locations
62 sites in 1 country. Site status is shown where the registry gives one.
Comprehensive Cancer Institute
Huntsville, Alabama
Western Regional Community Clinical Oncology Program
Phoenix, Arizona
Little Rock Hematology Oncology Assoc.
Little Rock, Arkansas
St. Jude Medical Center
Fullerton, California
Wilshire Oncology Medical Group
La Verne, California
Cedars-Sinai Medical Center
Los Angeles, California
UCLA School of Medicine
Los Angeles, California
Gynecologic Oncology Associates
Newport Beach, California
University of California, Irvine
Orange, California
Sharp Memorial Hospital
San Diego, California
Stanford University
Stanford, California
Rocky Mountain Cancer Center-Midtown
Denver, Colorado
University of Connecticut Cancer Center
Farmington, Connecticut
Northwestern Connecticut Oncology Hematology Associates, LLP
Torrington, Connecticut
Florida Gynecologic Oncology
Fort Myers, Florida
Florida Hospital Cancer Institute
Orlando, Florida
Pensacola Research Consultants
Pensacola, Florida
H. Lee Moffitt Cancer Center and Research
Tampa, Florida
Medical College of Georgia
Augusta, Georgia
The University of Chicago Hospitals
Chicago, Illinois
St. Vincent Gynecologic Oncology
Indianapolis, Indiana
Michiana Hematology Oncology PC
South Bend, Indiana
Brown Cancer Center
Louisville, Kentucky
Louisville Oncology
Louisville, Kentucky
Lake Charles Medical Surgical Clinic
Lake Charles, Louisiana
Hematology and Oncology Specialists
New Orleans, Louisiana
The Harry and Jeanette Weinberg Cancer Institute
Baltimore, Maryland
New England Medical Center
Boston, Massachusetts
Women's Specialty Center
Jackson, Mississippi
Ellis Fischel Cancer Center
Columbia, Missouri
Jersey Shore Medical Center
Neptune City, New Jersey
North Shore University Hospital
Manhasset, New York
St. Vincent's Comprehensive Cancer Center
New York, New York
Nyack Hospital
Nyack, New York
SUNY-HSC Syracuse, Crouse Hospital
Syracuse, New York
Blumenthal Cancer Center
Charlotte, North Carolina
Duke University Medical Center
Durham, North Carolina
University Hospital - Health Systems
Cleveland, Ohio
GYN Oncology and Pelvic Surgery Associates
Columbus, Ohio
ProMedica Health Systems
Toledo, Ohio
Showing 40 of 62 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.